Approximately 43,000 fallopian tube cancer cases were diagnosed in the US in 2011. Among fallopian tube cancer patients, younger age, black gender and the presence of family history are associated with advanced disease at time of presentation.
It has been demonstrated that the main germ line cancer susceptibility mutations in BRCA2 and BRCA1 confer an increased risk of developing epithelial ovarian cancer as well as fallopian tube cancer. Although the precise mechanism by which BRCA1/2 causes ovarian cancer is unknown, fallopian tube cancer is thought to result from a malfunction in cells or genes involved in genomic stability.
There is no cure for Fallopian cancers. Their management is highly dependent on the surgical treatment and chemotherapy used. As a result, management of Fallopian tubes is primarily symptomatic. Treatment may include chemotherapy and surgery.
Complications are observed in most of patients undergoing surgery of the ovary and fallopian tube. One out of ten of patients develop ovarian cancer later in life and 5% of these patients are diagnosed on the fallopian tube.
Fallopian tube cancer can present with the above signs of other gynecological cancers. It arises from ectopic endometrial-type tissue in the fallopian tube, but the signs of the disease are not as characteristic as in ovarian cancer.
Patient reported health status, as well as QOL (objective), improved following a trial of Dpx-survivac. The improvement in patient QOL appeared to continue at 12-month follow-up. Randomized controlled trials of a single agent with an evidence base for treatment are a good way to demonstrate cost effectiveness for health care providers. Results from a recent paper support the continued investigation of Dpx-survivac as a treatment for fallopian tube cancer.
Since there is no published evidence in the literature of the effectiveness or efficacy of DPX-SI-based combinations involving other common or novel treatments, more rigorous, randomized, and controlled trials are needed to assess the effectiveness and efficacy of these treatments. The use of DPX-SI-based mixtures on its own, irrespective of combination strategies, is probably not advisable for patients with FIGO stage I and II disease, since this treatment regimen should be used in combination with other more conventional treatment options.
Dpx-survival is a reliable method for selecting women most likely to respond to the addition of gemcitabine to surgery in early stage serous epithelial ovarian cancer: it could be incorporated into clinical protocols. © 2016 John Wiley & Sons, Ltd.
This was the first trial investigating dpx-survivac in treating patients with advanced ovarian cancer. Dpx-survivac did not significantly increase patient survival. Most of the patients had a progressive response to platinum, paclitaxel and/or ifosfamide-based treatment.
Fallopian tube cancer is uncommon in women with HSD and usually manifests late and presents with advanced-stage disease at diagnosis. This information may be helpful in informing high-risk women about the potential burden of fallopian tube cancer and identifying high-priority areas for further research and screening to reduce the devastating impact of this disease in women with an HSD.
Although the epidemiology and etiology of the disease is not completely understood, fallopian tube cancer is known to occur more frequently in women aged 40-48 years.